表紙
市場調査レポート

エピジェネティクスのR&D・治療薬・診断製品:産業および市場の展望

Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024

発行 Visiongain Ltd 商品コード 306489
出版日 ページ情報 英文 254 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.04円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
エピジェネティクスのR&D・治療薬・診断製品:産業および市場の展望 Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024
出版日: 2014年06月25日 ページ情報: 英文 254 Pages
概要

エピジェネティクスの利用は癌を含む疾病の診断および治療において大きな可能性を秘めています。世界のエピジェネティクス治療薬・診断製品・技術の市場は2018年には42億7,900万ドルの規模に成長し、2024年に向けてさらに大きく成長すると予測されています。

当レポートでは、エピジェネティクスを利用した治療薬、診断製品、技術の市場について調査し、エピジェネティクスの定義、治療薬部門、診断製品部門、技術部門のそれぞれにおける主要動向、主要技術・製品、市場成長予測、市場影響因子の分析、主要国市場における動向、R&Dの動向、インタビューなどを詳細にわたってまとめています。

第1章 レポート概要

第2章 イントロダクション:エピジェネティクスと医薬品業界における利用

  • エピジェネティクスの定義
  • エピジェネティクスと疾病の関係性
  • 疾病診断におけるエピジェネティクス
  • 疾病治療におけるエピジェネティクスの利用
  • 創薬とエピジェネティクスを利用した開発ツール

第3章 世界のエピジェネティック治療薬・技術・診断製品市場の予測

  • 世界のエピジェネティック治療薬・技術・診断製品市場
  • エピジェネティック治療薬・技術・診断製品:世界市場の予測
    • 収益予測
    • 成長の障壁
    • 市場シェアの予測
  • エピジェネティック治療薬部門の予測
    • 収益予測
    • 収益の重要性の拡大
  • エピジェネティック技術部門の予測
    • 収益予測
    • 成長推進因子・阻害因子
  • エピジェネティック診断製品部門の予測
    • 収益予測
    • 成長推進因子:新製品の投入

第4章 主要国市場の予測

  • 主要国市場
  • 主要国市場の収益予測
  • 北米市場の予測
  • EU市場:収益実績
  • 日本市場:エピジェネティクスへの関心の拡大
  • 新興国市場におけるエピジェネティクス

第5章 エピジェネティック治療薬市場の予測

  • エピジェネティック治療薬市場の将来の予測
  • Vidaza (Celgene Co. / 日本新薬):エピジェネティクス市場初の治療薬
  • Dacogen (Eisai/ Janssen-Cilag/ 大塚製薬)
  • Zolinza (Merck & Co./ 大鵬薬品工業)
  • Istodax:Celgene Co.によるエピジェネティクス市場で二番目の治療薬
  • エピジェネティック治療薬市場:HDAC阻害薬の多くのパイプライン
  • HDAC分野の新しい創薬
  • DNMT阻害薬のR&Dパイプライン
  • 他のエピジェネティクス酵素を標的としたパイプライン治療薬
  • MiRNA治療のパイプライン
  • 主なエピジェネティック治療薬の製造業者・開発事業者
    • Celgene:市場のリーダー
    • エーザイ
    • Janssen-Cilag
    • 大塚製薬
    • Merck & Co.
    • TopoTarget(BioAlliance Pharma SA)
    • Syndax Pharmaceuticals
    • 4SC
    • Curis
    • CellCentric
    • Constellation Pharmaceuticals
    • EpiTherapeutics
    • Epizyme
    • IkerChem
    • Karus Therapeutics

第6章 エピジェネティック技術:市場の予測

  • エピジェネティック技術・サービス市場の予測
  • 次世代シーケンシング(NGS)
  • クロマチン免疫沈降の未来
  • バイサルファイトスクリーニングの将来の発展
  • ハイスループットスクリーニング
  • エピジェネティクス技術の主要プロバイダー

第7章 エピジェネティック診断製品市場の予測

  • エピジェネティック診断製品市場の発展見通し
  • エピジェネティック診断製品市場
  • エピジェネティック診断製品のR&Dパイプライン
  • エピジェネティック診断製品の主要開発事業者

第8章 エピジェネティクスのR&D戦略

  • エピジェネティクス治療薬・技術・診断製品市場:疾病別
  • 現在および将来の癌におけるエピジェネティクス研究
  • 自己免疫疾患のDNAハイポメチル化の役割
  • 神経変性疾患
  • 神経疾患
  • 新しいエピジェネティック治療薬の標的

第9章 エピジェネティック治療薬・診断製品・関連技術:産業・市場動向の予測

  • 強み・弱み
  • 市場機会と脅威
  • STEP分析

第10章 リサーチインタビュー

  • Eric Marcotte博士(CEEHRC:Environment and Health Research Consortium)

第11章 総論

図表

目次

Epigenetics market - new analysis showing you technological trends and sales forecasts

Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts.

Visiongain's updated report shows you what's possible for those drugs, diagnostic tests and related technology. Avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales rises. See now how you can gain.

Assess technologies, products and services, benefiting your reputation for technological, medical and commercial insight. Read on, then, to explore that market and see its potential.

Forecasts and other information showing technical, clinical and business prospects

That new study gives you sales predictions to 2024 at overall world market, submarket, product and national level. See what the future holds for that emerging industry. For epigenetics you investigate where demand, opportunity and money lie.

Epigenetic uses hold great potential for diagnosing and treating diseases, including cancer.

There hear what's possible. And avoid struggles to find information. Besides giving revenue predictions, our analysis shows historical results, growth rates and market shares.

In that work you discover 72 tables, 57 charts and an interview. There help your research, analyses and decisions, also benefiting your influence and staying ahead.

And the following sections explain what our new investigation gives.

World market and its segments - what revenues possible from 2014 to 2024?

What's the commercial potential of epigenetics? Find in our report overall world revenue to 2024 for those products and technologies.

Also find individual revenue predictions to 2024 for three epigenetic submarkets at world level:

  • Therapies
  • Technologies for research
  • Diagnostics

What're the secrets of progress? There you assess outlooks for trade expansion, hearing where you could benefit. That work investigates products, uses and rising sales. You find commercial prospects.

That study also predicts and discusses leading epigenetic medicines' sales potentials.

Revenue predictions for leading drugs and expected therapies

Our study forecasts revenues of top brands - four leading agents and two therapies awaiting launch. There you see individual revenue forecasts to 2024 for these products:

  • Vidaza
  • Dacogen
  • Zolinza
  • Istodax

And you gain predictions for these expected treatments:

  • Beleodaq
  • Faridak

There you explore drugs and years with highest predicted sales. Also you examine competitors. You see what's happening there, understanding, challenges, trends and outlooks.

For that overall market, the report also shows geographical revenue predictions.

Sales in leading national markets - what outlooks for epigenetics?

Advances in pharmaceuticals, biotechnology and healthcare expand use of epigenetic services and products. See their prospects in developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for eight national markets and two regions:

  • United States (US)
  • Japan
  • Canada
  • Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
  • Brazil, Russia, India and China (BRIC nations, grouped analysis).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain. The study explains, helping you stay ahead.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Strengths, challenges and events - what affects epigenetics?

The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these forces:

  • Uses for epigenetics in cancer, inherited disorders and neurological diseases
  • DNA methlytransferase (DNMT) inhibition
  • Histone deacetylase (HDAC) inhibitors
  • Drug discovery and development using epigenetics
  • Bisulphite screening for DNA methylation.

And you explore these influences and opportunities, among others:

  • Chromatin immunoprecipitation (ChIP) for histone modification
  • Chemogenic approaches to spatiotemporal regulation of HDAC activity
  • Lysine pathways and acetylation-independent mechanisms
  • DNMT inhibition and targeting other epigenetic enzymes
  • Applications of genomics, proteomics and metabolomics
  • Targeting orphan diseases and subpopulations - personalised and stratified medicine.

You explore what progress, trends and prospects mean. And you discover what benefits and restrains companies, affecting commercial performance. So what does the future hold?

Epigenetics - leading companies and 2018 market value

From 2014, applications of epigenetics hold great potential for investments, technological advances and sales. What happens next?

Our new report predicts the world market for those products and technologies will reach $4,279m in 2018, with high further sales growth to 2024.

There you also see what organisations shape that industry:

  • Celgene
  • Eisai
  • Roche
  • Janssen-Cilag
  • Otsuka Pharmaceuticals
  • Merck & Co.

You also assess activities of these firms:

  • TopoTarget
  • Syndax Pharmaceuticals
  • MDxHealth
  • Epigenomics
  • Life Technologies
  • Qiagen, 4SC, EMD Millipore, Orion Genomics, DiscoveRx, EpiTherapeutics and others.

R&D in that industry holds strengths. And from 2014 there will arise many opportunities. From this decade onwards, patients, payers and companies will benefit. See how.

Ways Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 helps

In three main ways our investigation helps your work:

  • Revenues to 2024 at overall world level, for 3 submarkets and 6 products - assess outlooks for development, production, marketing and sales
  • Forecasts to 2024 for eight national markets and two regions - investigate developed and developing countries for revenues and sales expansion
  • Prospects for established competitors, rising companies and new entrants - explore products, R&D, opinions, and outlooks for success.

Knowledge there found nowhere else, benefiting your research, analyses and plans

Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.

With that investigation you're less likely to fall behind in data or miss opportunity. Discover there how you can benefit your information searches, analyses and decisions. Also find how you could save time and gain in authority.

Our new study is for everyone assessing the present and future of epigenetics. Your choosing that analysis shows you results, trends, opportunities and sales predictions. So discover potential gains by getting that report here now.

Table of Contents

1. Report Overview

  • 1.1 Epigenetic Therapies, Technologies and Diagnostics: World Market Review
  • 1.2 Global Epigenetics Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Main Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methods of Research and Analysis
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Introduction to Epigenetics and Uses in Pharma

  • 2.1 How is Epigenetics Defined?
    • 2.1.1 Epigenetic Mechanisms
    • 2.1.2 A Brief History of Epigenetic Research
  • 2.2 The Links between Epigenetics and Disease
    • 2.2.1 The Role of Lifestyle in Epigenetics
    • 2.2.2 Epigenetics and Cancer
    • 2.2.3 Epigenetics in Inherited Disorders
    • 2.2.4 Epigenetics in Neurological Diseases
  • 2.3 Epigenetics in Disease Diagnosis
    • 2.3.1 Diagnosing for Breast Cancer
    • 2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
    • 2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
    • 2.3.4 Diagnostics for Prostate Cancer
  • 2.4 The Use of Epigenetics in Treating Diseases
    • 2.4.1 DNA Methlytransferase (DNMT) Inhibitors
      • 2.4.1.1 Myelodysplastic Syndrome (MDS)
    • 2.4.2 Histone Deacetylase (HDAC) Inhibitors
      • 2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
      • 2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
  • 2.5 Drug Discovery and Development Tools Using Epigenetics
    • 2.5.1 Bisulphite Screening for DNA Methylation
    • 2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification

3. The Global Epigenetic Therapies, Technologies and Diagnostics Market 2014-2024

  • 3.1 The Global Epigenetic Therapies, Technologies and Diagnostics Market in 2013
    • 3.1.1 Leading Segments of the Market in 2013
  • 3.2 The Epigenetic Therapies, Technologies and Diagnostics Global Market 2014-2024
    • 3.2.1 The Epigenetic Therapies, Technologies and Diagnostics Global Market: Revenue Forecasts 2014-2024
    • 3.2.2 What Will Expedite the Growth of Epigenetic Therapies, Technologies and Diagnostics Market?
    • 3.2.3 Increase in Epigenetic Diagnostics Market Share 2014-2024
  • 3.3 Epigenetic Therapies Submarket 2014-2024
    • 3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2014-2024
    • 3.3.2 Rising Importance of Epigenetic Therapies Revenue 2014-2024
  • 3.4 Epigenetic Technologies Submarket 2014-2024
    • 3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2014-2024
    • 3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2014-2024
  • 3.5 Epigenetic Diagnostics Submarket 2014-2024
    • 3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2014-2024
    • 3.5.2 Growth Driving Factor: New Product Launches 2014-2024

4. Leading National Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024

  • 4.1 Leading National Markets for Epigenetic Therapies, Technologies and Diagnostics 2013
  • 4.2 Leading National Markets: Revenue Forecasts 2014-2024
    • 4.2.1 Global Market Will Be Dominated by the Western Countries 2014-2024
  • 4.3 The Northern American Market 2014-2024
    • 4.3.1 The US: The World's Largest Market for the Epigenetic Therapies, Technologies and Diagnostics 2014-2024
    • 4.3.2 Canada: Revenue Forecast 2014-2024
  • 4.4 European Union (EU) Epigenetics Market: Revenues 2013
    • 4.4.1 Leading National Markets in EU: Revenue Forecasts 2014-2024
    • 4.4.2 Germany: Revenue Forecast 2014-2024
    • 4.4.3 The UK: A Leading Country for Epigenetic Research
  • 4.5 Japanese Market: Increased Interest in Epigenetics
  • 4.6 Epigenetics in Emerging National Markets
    • 4.6.1 BRIC Nations: Positive Growth Expected in Epigenetic Therapies, Technologies and Diagnostics Markets 2014-2024

5. Epigenetic Therapies Market 2014-2024

  • 5.1 The Future of the Epigenetic Therapies Market 2014-2024
  • 5.2 Vidaza (Celgene Co. / Nippon Shinyaku): The First Therapy in the Epigenetic Market
    • 5.2.1 Vidaza: Leading Epigenetic Therapy 2004-2012
    • 5.2.2 How Was Vidaza Affected by Patent Expiry?
    • 5.2.3 Will Oral Azacitidine and Combination Therapy Stimulate Vidaza Growth?
    • 5.2.4 Vidaza: Revenue Forecast 2014-2024
  • 5.3 Dacogen (Eisai/ Janssen-Cilag/ Otsuka Pharmaceutical Co.)
    • 5.3.1 Dacogen: Historical Revenue Performance 2006-2012
    • 5.3.2 EU Approval and Combination Therapy to Drive Sales Growth?
    • 5.3.3 Will Oral Azacitidine and Combination Therapy Drive Vidaza Growth?
    • 5.3.4 Dacogen: Revenue Forecast 2014-2024
  • 5.4 Zolinza (Merck & Co./ Taiho Pharmaceutical)
    • 5.4.1 Zolinza for Multiple Myeloma Treatment
    • 5.4.2 Zolinza Revenue Forecast 2014-2024
  • 5.5 Istodax: Second Epigenetic Drug by Celgene Co.
    • 5.5.1 Istodax: Strong Revenue Growth 2010-2011
    • 5.5.2 International Market Approvals to Drive Growth?
    • 5.5.3 Istodax: Revenue Forecast 2014-2024
  • 5.6 Epigenetic Therapy Market 2013: Rich Pipeline for HDAC Inhibitors
    • 5.6.1 Beleodaq (TopoTarget/ Spectrum Pharmaceuticals): A Novel HDAC Inhibitor
    • 5.6.2 Faridak (Novartis): Treatment for Velcade-Refractory Multiple Myeloma
    • 5.6.3 Entinostat (Syndax Pharmaceuticals, Inc.): Breast and Lung Cancer
    • 5.6.4 Resminostat (4SC/ Yakult Honsha Co.): Hepatocellular Carcinoma
    • 5.6.5 Pracinostat (MEI Pharma): Treatment for MDS and AML
    • 5.6.6 Mocetinostat: Initiatives of Mirati Therapeutics to Drive Development
    • 5.6.7 Quisinostat (Janssen Pharmaceutica, NV/ NewVac LLC)
    • 5.6.8 Rocilinostat (Acetylon Pharmaceuticals): One of Celgene's Keen Interest
    • 5.6.9 CHR-3396 (Chroma Therapeutics)
    • 5.6.10 Givinostat (Italfarmaco): Chronic Myeloproliferative Neoplasms and Duchenne Muscular Dystrophy
    • 5.6.11 Shape (TetraLogic Pharmaceuticals): The First Topical HDAC inhibitor for CTCL
    • 5.6.12 FRM-0334 (Forum Pharmaceuticals Inc): Neurodegenerative Diseases
    • 5.6.13 4SC-202: Second Epigenetic Drug by 4SC Has Potential for Wider Indications
    • 5.6.14 Tefinostat (Chroma Therapeutics): Haematological Cancer
    • 5.6.15 CDX10 (Celleron Therapeutics): Part of Personalised Cancer Treatment Trial
    • 5.6.16 RG2833 (The Scripps Research Institute): Friedreich's Ataxia
    • 5.6.17 Abexinostat (Pharmacyclics)
  • 5.7 New Discoveries in the Field of HDAC 2013
    • 5.7.1 Chemogenic Approaches to Spatiotemporal Regulation of HDAC Activity
    • 5.7.2 Novel Lysine Pathways and Acetylation-Independent Mechanisms of HDACs
    • 5.7.3 HDAC Inhibitor: Treatment of Pathological Muscle Remodelling
    • 5.7.4 Design of Class I Isoform Selective Inhibitors for Use in Metabolic Indications
    • 5.7.5 Zinc Binding Groups Inhibit Class IIa HDAC and Alters Immune Responses
  • 5.8 DNMT Inhibitor R&D Pipeline 2013
    • 5.8.1 SGI-110 (Otsuka Pharmaceuticals): A Second Generation DNMT Inhibitor
    • 5.8.2 FdCyd (National Cancer Institute): Solid Tumours
    • 5.8.3 Hydralazine: Being Tested in 23 Clinical Trials
    • 5.8.4 MG98 (Mirati Therapeutics)
    • 5.8.5 CP-4200: A Second Generation Vidaza
    • 5.8.6 RX3117 (Rexahn Pharmaceuticals)
  • 5.9 Pipeline Treatments Targeting Other Epigenetic Enzymes 2013
    • 5.9.1 EPZ-5676 (Epizyme Inc./ Celgene Co.): The First Clinical-Stage HMT Inhibitor
    • 5.9.2 EPZ-5676 (Epizyme Inc./ Eisai): The Second Clinical-Stage HMT Inhibitor
    • 5.9.3 ORY-1001(Roche): Orphan Drug Status in Early Stage AML
    • 5.9.4 SP-2528 (Salarius Pharmaceuticals)
    • 5.9.5 RVX-208 (Resverlogix): Advancing BET Protein Inhibitors
  • 5.10 MiRNA Therapy Pipeline 2013
    • 5.10.1 Miravirsen (Santaris Pharma A/S): The First miRNA Therapy to Enter Human Clinical Trial
    • 5.10.2 MRX34 (Mirna Therapeutics)
    • 5.10.3 Collaborations of Regulus Therapeutics with Big Pharma Players
  • 5.11 Leading Epigenetic Therapy Manufacturers and Developers
    • 5.11.1 Celgene: Market Leader in 2013
    • 5.11.2 Eisai
    • 5.11.3 Janssen-Cilag
    • 5.11.4 Otsuka Pharmaceuticals
    • 5.11.5 Merck & Co.
    • 5.11.6 TopoTarget to Merge with BioAlliance Pharma SA
    • 5.11.7 Syndax Pharmaceuticals
    • 5.11.8 4SC
    • 5.11.9 Curis: Focusing on Multi-Targeted Treatments
    • 5.11.10 CellCentric: Collaborating with Big Pharma for Drug Development
    • 5.11.11 Constellation Pharmaceuticals
    • 5.11.12 EpiTherapeutics
    • 5.11.13 Epizyme: Signed Multiple Collaboration Agreements with Big Pharma
    • 5.11.14 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
    • 5.11.15 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer

6. Epigenetic Technologies: Markets 2014-2024

  • 6.1 Epigenetic Technologies and Services Market 2014-2024
    • 6.1.1 Should Epigenetic Discovery and Analysis Be Outsourced?
  • 6.2 Next Generation Sequencing (NGS)
    • 6.2.1 Higher Speed and Reduced Costs for Epigenetic Research
    • 6.2.2 Are Current Bioinformatic Programmes a Setback?
    • 6.2.3 Single Molecule Sequencing to Compete with NGS
  • 6.3 The Future of Chromatin Immunoprecipitation
    • 6.3.1 ChIP-Seq
  • 6.4 Future Developments in Bisulphite Screening
    • 6.4.1 Importance of Techniques to Distinguish 5hmC
  • 6.5 High Throughput Screening
  • 6.6 Leading Providers of Epigenetics Technologies 2013
    • 6.6.1 Active Motif
    • 6.6.2 Measurement Tools for Epigenetic Research by Agilent Technologies
    • 6.6.3 Diagenode: Best -In-Class Methyl Binding Domain Based Kit
    • 6.6.4 DiscoveRx
    • 6.6.5 EMD Millipore
    • 6.6.6 Epigenetek: Specialist in Epigenetic Technologies
    • 6.6.7 Epiontis: Assessing Purity in Regenerative Medicine Products
    • 6.6.8 Life Technologies: Reducing NGS Process Cost
    • 6.6.9 Qiagen: Epigenetic Technologies and Diagnostics
    • 6.6.10 Roche

7. Epigenetic Diagnostics Market 2014-2024

  • 7.1 Development of the Epigenetic Diagnostics Market 2014-2024
    • 7.1.1 LDTs vs. IVDs: Two Diagnostics Development Strategies
  • 7.2 Epigenetic Diagnostics Market 2013
    • 7.2.1 Epi proColon 2.0 (Epigenomics)
    • 7.2.2 ColoVantage (Quest Diagnostics)
    • 7.2.3 Septin9 LDT (ARUP Laboratories)
    • 7.2.4 ColoSure (LabCorp)
    • 7.2.5 ConfirmMDx for Prostate Cancer
    • 7.2.6 Gene Methylation in Prostate Cancer (LabCorp)
    • 7.2.7 Epi proLung (Epigenomics)
    • 7.2.8 MGMT Gene Methylation Assay (LabCorp)
    • 7.2.9 PredictMDx (MDxHealth): Brain Cancer
    • 7.2.10 Bladder Cancer Testing with CertNDx (Physician's Choice Laboratory Services)
  • 7.3 Epigenetic Diagnostics R&D Pipeline 2013
    • 7.3.1 The Future of Colorectal Cancer Testing
      • 7.3.1.1 Cologuard: Improved Sensitivity
      • 7.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
    • 7.3.2 Pipeline of Prognostic Tools for Prostate Cancer
    • 7.3.3 Lung Cancer
      • 7.3.3.1 Lung Cancer Screening Test (Orion Genomics)
      • 7.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
    • 7.3.4 The Future of Bladder Cancer Testing
      • 7.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
    • 7.3.5 Other Cancer Tests Pipeline 2013
      • 7.3.5.1 Pancreatic Cancer Prognostic Test (PrognosticDx Health)
  • 7.4 Leading Epigenetic Diagnostic Developers 2013
    • 7.4.1Epigenomics: Multiple Tests Marketed in the EU
      • 7.4.1.1 Positive Revenue Growth 2012-2013
    • 7.4.2 Exact Sciences: Colorectal Cancer Screening
    • 7.4.3 MDxHealth: Targeting the US Diagnostics Markets
      • 7.4.3.1 Strong Revenue Growth 2009-2013
    • 7.4.4 Orion Genomics: More than 100 Markers Have Been Discovered
    • 7.4.5 Physician's Choice Laboratory Services (PCLS)
    • 7.4.6 PrognosDx Health: Developing Epigenetic Prognostics

8. Research and Product Development Strategies in Epigenetics 2014

  • 8.1 Epigenetics Therapies, Technologies and Diagnostics Market by Disease 2014-2024
  • 8.2 Present and Future Epigenetic Research in Cancer
    • 8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
    • 8.2.2 Colorectal Cancer: More Than Two Biomarkers Established
    • 8.2.3 Lung Cancer: Prognostic Markers
    • 8.2.4 Prostate Cancer: The Need for Progression in Epigenetic Therapies
  • 8.3 The Role of DNA Hypomethylation in Autoimmune Diseases
    • 8.3.1 Lupus
    • 8.3.2 Rheumatoid Arthritis as a Target for Drugs and Diagnostics
      • 8.3.2.1 Ignyta: Pioneer in Epigenetic Diagnostic for Rheumatoid Arthritis
    • 8.3.3 Prevalence of Diabetes linked to Diet and Ageing
  • 8.4 Neurodegenerative Diseases
    • 8.4.1 Alzheimer's Disease: Symptoms Improved with HDAC Inhibitors
    • 8.4.2 Huntington's Disease: Epigenetic Drugs in Clinical Development
  • 8.5 Neurological Disorders
    • 8.5.1 Drug Resistance in Schizophrenia
    • 8.5.2 Hundreds of Genetic and Epigenetic Mutations linked to Autism
  • 8.6 New Epigenetic Therapy Targets
    • 8.6.1 BET Proteins Targeted by Multiple Therapeutic Areas
    • 8.6.2 Importance of DNA Hydroxymethylation
    • 8.6.3 Sirtuins: Undergoing Limited Research
    • 8.6.4 Histone Methyltranferase
      • 8.6.4.1 Lysine Methyltranferase
      • 8.6.4.2 Domainex: Development of HMT Inhibitor
      • 8.6.4.3 Protein Arginine Methyltransferases: The Need for Improved Potency
      • 8.6.4.4 Lysine Demethylases: Potential Cancer Treatment Target

9. Epigenetic Therapies, Diagnostics and Related Technologies: Industry and Market Trends 2014-2024

  • 9.1 Epigenetic Therapies, Technologies and Diagnostics: Strengths and Weaknesses 2014-2024
    • 9.1.1 Understanding Epigenetic Markers and Mechanisms
    • 9.1.2 Specificity of Marketed Epigenetic Therapies
  • 9.2 Epigenetics Therapies, Technologies and Diagnostics Market Opportunities and Threats 2014-2024
    • 9.2.1 The Important Role of Translational Research
    • 9.2.2 Development of Companion Diagnostics in Conjunction with Therapies
    • 9.2.3 Rich Therapeutic and Diagnostic Pipelines
    • 9.2.4 Combination Therapy with Epigenetic Drugs Show Promise
    • 9.2.5 Epigenetic Drugs to Succeed Drug Resistance
    • 9.2.6 Therapy Target Scope besides HDAC and DNMT Inhibition
  • 9.3 Epigenetics Therapies, Technologies and Diagnostics: STEP Analysis 2014-2024
  • 9.4 Social Factors Affecting Epigenetic Product Development
    • 9.4.1 The Influence of Environment
    • 9.4.2 The Role of Epigenetics in Ageing and Diseases
      • 9.4.2.1 Increasing Prevalence of Global Disease to Drive Epigenetics Market Growth
    • 9.4.3 Targeting Orphan Diseases and Patient Subpopulations
    • 9.4.4 Use of Epigenetics in Personalised and Stratified Medicine
  • 9.5 Advancing Epigenetic Technologies to Support Epigenetic Research
    • 9.5.1 NGS: Improving the Quality of Epigenetic Research
    • 9.5.2 Epigenetics to Help Drive Stem Cell Research Development
    • 9.5.3 Complementary and Competing Forces
      • 9.5.3.1 Genomics
      • 9.5.3.2 Proteomics
      • 9.5.3.3 Metabolomics
  • 9.6 Economic Factors
    • 9.6.1 Recent Developments Helped Reduce Costs in Epigenetic Research
    • 9.6.2 Importance of Big Pharma in Epigenetic Markets 2014-2024
      • 9.6.2.1 Pfizer
      • 9.6.2.2 Novartis
      • 9.6.2.3 GSK: Part of Multiple Agreements in Epigenetics
    • 9.6.3 Valuable Licensing Deals in Epigenetics
    • 9.6.4 Epigenetic Business Models
  • 9.7 Political Issues
    • 9.7.1 Ethics in Epigenetic Research
    • 9.7.2 Global Collaboration to Expedite Market Growth
      • 9.7.2.1 Structural Genome Consortium
      • 9.7.2.2 Roadmap Epigenomics Project (NIH)
      • 9.7.2.3 International Human Epigenome Consortium
      • 9.7.2.4 Blueprint Project

10. Research Interview

  • 10.1 Interview with Dr Eric Marcotte, Strategic Lead, Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
    • 10.1.1 Canadian Institute of Health Research: Interest in Epigenetics
    • 10.1.2 Canadian Epigenetic Therapy Market
    • 10.1.3 Prominent Epigenetic Therapeutic Areas in the Future
    • 10.1.4 Promising New Epigenetic Therapy and Diagnostics
    • 10.1.5 Future of Canadian Epigenetics Market
    • 10.1.6 CIHR and JST Partnership Outcome

11. Conclusions from the Research and Analysis

  • 11.1 Therapies Submarket Accounts for Most of the Epigenetic Market Revenues in 2013
  • 11.2 Growth Expected in All Submarkets of the Epigenetic Market 2014-2024
    • 11.2.1 Developed National Pharma Markets to Lead, 2014-2024
  • 11.3 Many Opportunities Exist in the Epigenetics Industry and Market

List of Tables

  • Table 1.1 Global Epigenetics Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
  • Table 2.1 Selected Enzymes Involved in Epigenetics
  • Table 2.2 Selected Treatments for MDS, 2013
  • Table 3.1 Epigenetic Therapies, Technologies and Diagnostics Sector: Global Market Size ($m) and Market Share (%), 2013
  • Table 3.2 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m), AGR (%) and CAGR (%) Forecast, 2013-2024
  • Table 3.3 Epigenetic Therapies, Technologies and Diagnostics: Submarket Shares (%), 2013-2024
  • Table 3.4 Epigenetic Therapies Submarket by Drug: Market Size ($m) and Market Share (%), 2013
  • Table 3.5 Epigenetic Therapies Submarket: Market Size ($m), AGR (%) and CAGR (%) Forecasts by Drug, 2013-2024
  • Table 3.6 Epigenetic Technologies Submarket: Global Market Size ($m) Forecast, 2013-2024
  • Table 3.7 Epigenetic Diagnostics Submarket: Global Market Size ($m) Forecast, 2013-2024
  • Table 4.1 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m) and Market Share (%) by Region, 2013
  • Table 4.2 Global Epigenetic Market Forecast: Market Size ($m), AGR (%) and CAGR (%) by Region, 2013-2024
  • Table 4.3 Epigenetic Therapies, Technologies and Diagnostics: Market Share (%) by Region, 2013-2024
  • Table 4.4 Epigenetic Therapies, Technologies and Diagnostics: US Market Size ($m) Forecast, 2013-2024
  • Table 4.5 Epigenetic Therapies, Technologies and Diagnostics: Canadian Market Size ($m) Forecast, 2013-2024
  • Table 4.6 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) and Market Share (%) by Leading Country, 2013
  • Table 4.7 Selected Epigenetics Companies with Headquarters in the EU, 2013
  • Table 4.8 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) Forecast, 2013-2024
  • Table 4.9 EU Epigenetics Therapies, Technologies and Diagnostics Market: Market Size ($m) Forecasts by Leading Country, 2013-2024
  • Table 4.10 Epigenetic Therapies, Technologies and Diagnostics: German Market Size ($m) Forecast, 2013-2024
  • Table 4.11 Epigenetic Therapies, Technologies and Diagnostics: UK Market Size ($m) Forecast, 2013-2024
  • Table 4.12 Epigenetic Therapies, Technologies and Diagnostics: Japanese Market Size ($m) Forecast, 2013-2024
  • Table 4.13 Epigenetic Therapies, Technologies and Diagnostics: BRIC Nations (Grouped) Market Size ($m) Forecast, 2013-2024
  • Table 5.1 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2013-2024
  • Table 5.2 Vidaza: Historical Revenue ($m), AGR (%) and CAGR (%), 2004-2013
  • Table 5.3 Vidaza: Revenue ($m) by Region, H2 2012-2013
  • Table 5.4 Celgene Sponsored Trials of Oral Vidaza (azacitidine), 2013
  • Table 5.5 Selected Late-Stage Clinical Trials of Vidaza (azacitidine), 2013
  • Table 5.6 Vidaza Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
  • Table 5.7 Dacogen: Historical Revenue ($m), Royalty Revenue ($m), AGR (%) and CAGR (%), 2006-2012
  • Table 5.8 Late-Stage Clinical Trials of Dacogen (decitabine), 2013
  • Table 5.9 Dacogen Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
  • Table 5.10 Multiple Myeloma Prevalence by Region, 2013
  • Table 5.11 Selected Late-Stage Clinical Trials of Zolinza (vorinostat), 2013
  • Table 5.12 Zolinza: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
  • Table 5.13 Istodax: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2013
  • Table 5.14 Phase III Clinical Trials of Istodax (romidepsin), 2013
  • Table 5.15 Istodax: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2013-2024
  • Table 5.16 Selected HDAC Inhibitors in Development, 2013
  • Table 5.17 TopoTarget/ Spectrum Pharmaceuticals Sponsored Clinical Trials of Beleodaq (belinostat), 2013
  • Table 5.18 Beleodaq: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
  • Table 5.19 Clinical Trials of Faridak (panobinostat), 2013
  • Table 5.20 Faridak: Revenue ($m) Forecast, AGR (%) and CAGR (%), 2015-2024
  • Table 5.21 Clinical Trials of Entinostat in Breast Cancer and Lung Cancer, 2013
  • Table 5.22 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
  • Table 5.23 Clinical Trials of Resminostat (4SC-201), 2013
  • Table 5.24 Clinical Trials of Pracinostat, 2013
  • Table 5.25 Clinical Trials of Rocilinostat (ACY-1215), 2013
  • Table 5.26 Clinical Trials of Givinostat (ITF2357), 2013
  • Table 5.27 Selected DNMT Inhibitors in Development, 2013
  • Table 5.28 Clinical Trials of SGI-110, 2013
  • Table 5.29 Clinical Trials of FdCyd (5-Fluoro-2'-deoxycytidine), 2013
  • Table 5.30 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2013
  • Table 5.31 Selected MiRNA Therapy Pipeline, 2013
  • Table 5.32 CellCentric's Research Institution Affiliations, 2012
  • Table 5.33 IkerChem Epigenetic Pipeline, 2013
  • Table 6.1 Fall in Average Cost ($m) of Sequencing the Human Genome, 2000-2013
  • Table 6.2 Advantages of Single Molecule Sequencing over Next Generation Sequencing, 2014
  • Table 6.3 Selected Producers of Single Molecule Sequencing Technologies, 2014
  • Table 6.4 Life Technologies: Revenues ($m) and AGR (%) by Sector, 2011-2012
  • Table 7.1 Marketed Epigenetic Colorectal Cancer Test Cost ($), Specificity (%) and Sensitivity (%) Comparison, 2013
  • Table 7.2 Epigenomics: Historical Revenue ($m), AGR (%) and CAGR (%), 2009-2013
  • Table 7.3 MDxHealth: Diagnostics Pipeline, 2013
  • Table 7.4 MDxHealth: Historical Revenue ($m) and CAGR (%) by Source, 2009-2013
  • Table 8.1 US Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
  • Table 9.1 Epigenetic Therapies, Technologies and Diagnostics Market: Strengths and Weaknesses, 2014
  • Table 9.2 Epigenetic Therapies, Technologies and Diagnostics Market: Opportunities and Threats, 2014-2024
  • Table 9.3 Epigenetic Therapies, Technologies and Diagnostics Market: STEP Analysis, 2014-2024
  • Table 9.4 Selected Licensing Deals for Epigenetic Therapies, 2011-2014
  • Table 9.5 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
  • Table 9.6 IHEC Member Organisations, 2013
  • Table 11.1 Epigenetic Market Size ($m), Market Share (%) and CAGR (%) by Submarket, 2013, 2018 and 2024
  • Table 11.2 Epigenetic Therapies, Technologies and Diagnostics Market Size ($m), Market Share (%) and CAGR (%) by Region, 2013, 2018 and 2024

List of Figures

  • Figure 1.1 Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
  • Figure 1.2 Global Epigenetics Market Segmentation, 2014
  • Figure 2.1 Stages of Cutaneous T Cell Lymphoma
  • Figure 2.2 Chromatin Immunoprecipitation (chIP) Process
  • Figure 3.1 Epigenetic Therapies, Technologies and Diagnostics Sector: Global Market Share (%), 2013
  • Figure 3.2 Epigenetic Therapies, Technologies and Diagnostics: Market Size ($m) Forecast, 2013-2024
  • Figure 3.3 Epigenetic Therapies, Technologies and Diagnostics Market: Drivers and Restraints, 2014-2024
  • Figure 3.4 Epigenetic Therapies, Technologies and Diagnostics: Submarket Shares (%), 2018
  • Figure 3.5 Epigenetic Therapies, Technologies and Diagnostics Submarket Shares (%), 2024
  • Figure 3.6 Epigenetic Therapies Submarket by Drug: Global Market Share (%), 2013
  • Figure 3.7 Epigenetic Therapies Submarket: Global Market Size ($m) Forecast, 2013-2024
  • Figure 3.8 Epigenetic Therapies Submarket: Drivers and Restraints, 2014-2024
  • Figure 3.9 Epigenetic Technologies Submarket: Global Market Size ($m) Forecast, 2013-2024
  • Figure 3.10 Epigenetic Technologies Submarket: Drivers and Restraints, 2014-2024
  • Figure 3.11 Epigenetic Diagnostics Submarket: Global Market Size ($m) Forecast, 2013-2024
  • Figure 3.12 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2014-2024
  • Figure 4.1 Epigenetic Therapies, Technologies and Diagnostics: Market Share (%) by Region, 2013
  • Figure 4.2 Epigenetic Therapies, Technologies and Diagnostics in Developed National Markets: Drivers and Restraints, 2014-2024
  • Figure 4.3 Epigenetic Therapies, Technologies and Diagnostics in Emerging National Markets: Drivers and Restraints, 2014-2024
  • Figure 4.4 Epigenetic Therapies, Technologies and Diagnostics Market Share (%) by Region, 2018
  • Figure 4.5 Epigenetic Therapies, Technologies and Diagnostics Market Share (%) by Region, 2024
  • Figure 4.6 Epigenetic Therapies, Technologies and Diagnostics: US Market Size ($m) Forecast, 2013-2024
  • Figure 4.7 Epigenetic Therapies, Technologies and Diagnostics: Canadian Market Size ($m) Forecast, 2013-2024
  • Figure 4.8 Epigenetics Therapies, Technologies and Diagnostics: EU Market Share (%) by Leading Country, 2013
  • Figure 4.9 Epigenetic Therapies, Technologies and Diagnostics: EU Market Size ($m) Forecast, 2013-2024
  • Figure 4.10 Epigenetics Therapies, Technologies and Diagnostics: French, Spanish and Italian Market Size ($m) Forecasts, 2013-2024
  • Figure 4.11 Epigenetic Therapies, Technologies and Diagnostics: German Market Size ($m) Forecast, 2013-2024
  • Figure 4.12 Epigenetic Therapies, Technologies and Diagnostics: UK Market Size ($m) Forecast, 2013-2024
  • Figure 4.13 Epigenetics Therapies, Technologies and Diagnostics: Japanese Market Size ($m) Forecast, 2013-2024
  • Figure 4.14 Epigenetics Therapies, Technologies and Diagnostics: BRIC Nations (Grouped) Market Size ($m) Forecast, 2013-2024
  • Figure 5.1 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2018
  • Figure 5.2 Epigenetic Therapies Submarket: Submarket Shares (%) by Drug, 2024
  • Figure 5.3 Vidaza: Historical Revenue ($m) and AGR (%), 2004-2013
  • Figure 5.4 Vidaza: Revenue ($m) by Region, H2 2012-2013
  • Figure 5.5 Vidaza Revenue ($m) Forecast, 2013-2024
  • Figure 5.6 Vidaza Revenue: Drivers and Restraints, 2014-2024
  • Figure 5.7 Vidaza and Dacogen: Chemical Structures
  • Figure 5.8 Dacogen: Historical Revenue ($m) and Royalty Revenue ($m), 2006-2012
  • Figure 5.9 Dacogen Revenue ($m) Forecast, 2013-2024
  • Figure 5.10 Dacogen Revenue: Drivers and Restraints, 2014-2024
  • Figure 5.11 Zolinza: Revenue ($m) Forecast, 2013-2024
  • Figure 5.12 Zolinza Revenue: Drivers and Restraints, 2014-2024
  • Figure 5.13 Istodax: Historical Revenue ($m) and AGR (%), 2010-2013
  • Figure 5.14 Istodax: Revenue ($m) Forecast, 2013-2024
  • Figure 5.15 Istodax Revenue: Drivers and Restraints, 2014-2024
  • Figure 5.16 HDAC Inhibitor Expected Approvals, 2015-2020
  • Figure 5.17 Beleodaq: Revenue ($m) Forecast, 2015-2024
  • Figure 5.18 Faridak: Revenue ($m) Forecast, 2015-2024
  • Figure 5.19 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer: Breakdown, 2012
  • Figure 6.1 Fall in Average Cost ($m) of Sequencing the Human Genome, 2000-2013
  • Figure 6.2 Life Technologies: Revenues ($m) by Sector, 2011-2012
  • Figure 7.1 Marketed Epigenetic Colorectal Cancer Test Cost ($), Specificity (%) and Sensitivity (%) Comparison, 2013
  • Figure 7.2 Epigenomics: Historical Revenue ($m) and AGR (%), 2009-2013
  • Figure 7.3 MDxHealth: Historical Revenue ($m) by Source, 2009-2013
  • Figure 8.1 Prevalence of Cancers Targeted by Epigenetic Therapies and Diagnostics, 2013
  • Figure 11.1 Epigenetic Market Size ($m) by Submarket, 2013, 2018 and 2024
  • Figure 11.2 Epigenetic Therapies, Technologies and Diagnostics Market Size ($m) by Region, 2013, 2018 and 2024

Companies Listed

  • 4SC
  • Abbott Laboratories (AbbVie)
  • Accelerate Brain Cancer Cure
  • Accium BioSciences
  • Acetylon Pharmaceuticals
  • Active Motif
  • Agence Nationale de la Recherche (ANR)
  • Agilent
  • American Association of Cancer Research (AACR)
  • American Cancer Society
  • American Medical Association
  • American Society of Clinical Oncology
  • American Society of Hematology
  • Amgen
  • ARUP Laboratories
  • Astellas Pharma
  • Astellas Venture Management
  • Astex Pharmaceuticals (Otsuka Pharmaceutical)
  • AstraZeneca
  • Aton Pharma (now part of Merck & Co.)
  • Australian Alliance for Epigenetics
  • Automation Partnership
  • Babraham Institute
  • Baxter
  • Bayer
  • BGI
  • BioAlliance Pharma SA
  • BioChain
  • Biogen Idec
  • BioMarin Pharmaceuticals
  • BioSeek
  • Biotech Research and Innovation Centre
  • Biotechnology and Biological Sciences Research Council
  • BLUEPRINT Epigenome Consortium
  • Boehringer Mannheim
  • Bristol-Meyers Squibb
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Cambridge Institute for Medical Research
  • Cambridge University
  • Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
  • Canadian Institute for Health Research (CIHR)
  • CanAm Bioresearch
  • Cancer Research Technology
  • Cancer Research UK
  • Celgene
  • CellCentric
  • Celleron Therapeutics
  • Cellzome
  • Center for Genomic Sciences (CGS)
  • Centre for Addiction and Mental Health (Canada)
  • Centre for Cancer Research
  • Centre for Genomic Regulation (Barcelona)
  • Centre National de la Recherche Scientifique (CNRS)
  • Ceptaris Therapeutics
  • ChemRar High Tech Center
  • Chiron
  • Chroma Therapeutics
  • City of Hope Medical Centre
  • Clavis Pharma
  • Committee for Medicinal Products for Human Use (CHMP)
  • Constellation Pharmaceuticals
  • Cornell University
  • CURELUNG
  • Curis
  • Cyclacel Pharmaceuticals
  • Dana-Farber Cancer Institute
  • Diagenode
  • DiscoveRX
  • Domainex
  • Dr. Reddy's Laboratories
  • Durviz
  • Eastern Cooperative Oncology Group
  • ECOG-ACRIN Cancer Research Group
  • Eisai
  • Eli Lilly
  • Elixir Pharmaceuticals
  • EMD Millipore (also known as Merck Millipore)
  • EnVivo Pharmaceuticals (now part of Forum Pharmaceuticals)
  • EpigenDx
  • EpiGeneSys
  • Epigenetics Dream Team
  • Epigenomics
  • Epigentek
  • Epiontis
  • EpiTherapeutics
  • Epizyme
  • e-Therapeutics
  • European Commission (EC)
  • European Institute of Oncology (IEO)
  • European Medicines Agency (EMA)
  • European Patent Office
  • Exact Sciences
  • Experimental Cancer Medicine Network (ECMC)
  • FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
  • Federal Ministry of Education and Research (BMBF)
  • FIRC Institute of Molecular Oncology Foundation (IFOM)
  • Flagship Biosciences
  • Forum Pharmaceuticals
  • Fresenius Kabi
  • Friedreich's Ataxia Research Alliance (FARA)
  • Genentech
  • Genpathway
  • German Cancer Research Center
  • GlaxoSmithKline (GSK)
  • Gloucester Pharmaceuticals (now part of Celgene)
  • Go FAR (Friedreich's Ataxia Research)
  • Harvard University
  • Health Canada
  • Health Genomics
  • Heptares Therapeutics
  • Hospital of Soochow University
  • Howard Hughes Medical Institute
  • Ignyta
  • IkerChem
  • Imperial College London
  • Indian Institute of Science Education and Research
  • Institute of Cancer Research
  • International Human Epigenome Consortium (IHEC)
  • Italfarmaco
  • Italian Institute of Technology (IIT)
  • Ivax LLC
  • Janssen Cilag
  • Janssen Pharmaceutica NV
  • Japan Science and Technology Agency (JST)
  • Japanese Society for Epigenetics
  • Jian-Xian Janssen Pharmaceuticals Ltd.
  • Johns Hopkins University
  • Kainos Medicine
  • Karus Therapeutics
  • Kindstar
  • King's College London
  • Krembil Family Epigenetics Laboratory
  • Kyowa Hakko Kirin Pharma Inc.
  • LabCorp
  • Leukemia & Lymphoma Society
  • Life Technologies' (now part of Thermo Fisher Scientific)
  • Louis Pasteur University of Strasbourg
  • Lundbeckfond Ventures
  • M.D. Anderson Cancer Center
  • Massachusetts General Hospital
  • Mayo Clinic
  • McGill University
  • MDxHealth
  • Medical Research Council
  • MEI Pharma
  • Memorial Sloan-Kettering Cancer Center
  • Merck & Co.
  • Merck KGaA
  • Merck Serono Ventures
  • MethylGene
  • MGI Pharma
  • Michael J. Fox Foundation for Parkinson's Research
  • Microgenics
  • Millennium Pharmaceuticals
  • MIMR-PHI Institute of Medical Research
  • Ministry of Health, Labour and Welfare (MHLW)
  • Mirati Therapeutics
  • MiReven
  • Mirna Therapeutics
  • Mitomics
  • Mount Sinai Medical Center
  • Multiple Myeloma Research Foundation
  • Muscular Dystrophy Association (MDA)
  • Myeloma UK
  • Myriad Genetics
  • National Ataxia Foundation (NAF)
  • National Cancer Institute
  • National Comprehensive Cancer Network (NCCN)
  • National Council of Science and Technology
  • National Health and Medical Research Council (NHMRC)
  • National Health Service (NHS, UK)
  • National Institute for Health and Clinical Excellence (NICE, UK)
  • National Institute for Mental Health
  • National Institute of Allergy and Infectious Disease (NIAID)
  • National Institute of Cancerología
  • National Institute of Health, Korea
  • National Institute of Mental Health
  • National Institutes of Health (NIH)
  • National Institutes of Health Clinical Center (CC)
  • NewVac
  • NIH Epigenomics Roadmap Project
  • Nippon Shinyaku
  • Nottingham University
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • Novo Nordisk
  • Nycomed
  • Odyssey Molecular
  • OncoMethylome (now MDxHealth)
  • Onxeo
  • Onyx Pharmaceuticals
  • Orion Genomics
  • Oryzon Genomics
  • Otsuka Pharmaceuticals
  • Oxford University
  • Oxford University Hospitals NHS Trust
  • Pacific Biosciences
  • Pfizer
  • Pharmacyclics
  • Pharmion by Pharmacia & Upjohn
  • Physician's Choice Laboratory Services
  • PLUS Diagnostics
  • Polymedco
  • Predictive Biosciences
  • PrognosDx Health
  • Project Management Agency with German Aerospace Center (PT-DLR)
  • Psicofarma S.A. de C.V.
  • Qiagen
  • Quest Diagnostics
  • Quest Laboratory
  • Regulus Therapeutics
  • Repligen
  • Resverlogix
  • Rexahn Pharmaceuticals
  • Roche
  • Roche's Translational Clinical Research Centre
  • Roswell Park Cancer Institute
  • S*BIO
  • SABiosciences
  • Salarius Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santaris Pharma AS
  • Scottish Medicines Consortium (SMC)
  • Seattle Genetics Inc
  • Seed Capital
  • Servier
  • Shape Pharmaceuticals
  • Sidney Kimmel Comprehensive Cancer Centre
  • Siena Biotech
  • Sigma-Aldrich
  • Spectrum Pharmaceuticals
  • Structural Genomics Consortium (SGC)
  • Swiss Life
  • SwitchGear Genomics
  • Syndax Pharmaceuticals
  • Sysmex
  • Taiho Pharmaceutical
  • Takeda Pharmaceutical Company
  • Tempero Pharmaceuticals
  • Tensha Therapeutics
  • TetraLogic Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Lymphoma Academic Research Organisation
  • Thermo Fisher Scientific
  • Thomas Jefferson University
  • TopoTarget
  • UK Funders Alliance
  • UK Technology Strategy Board
  • United States District Court
  • University College London (UCL)
  • University of Birmingham
  • University of California, Los Angeles (UCLA)
  • University of Chicago
  • University of Leeds
  • University of North Carolina
  • University of the Basque Country
  • University of Toronto
  • University of Edinburgh
  • US Food and Drug Administration (FDA)
  • US National Cancer Institute
  • Ventana Medical Systems
  • Warnex
  • Wellcome Trust
  • Wistar Institute
  • World Health Organization (WHO)
  • Yakult Honsha Co.
  • ZoBio
Back to Top